Endometrial Cancer Clinical Trial
Official title:
A Phase 1/2 Study of CPI-0209 in Patients With Advanced Solid Tumors and Lymphomas
First-in-human, open-label, sequential dose escalation and expansion study of CPI-0209 in patients with advanced solid tumors and lymphomas. CPI-0209 is a small molecule inhibitor of EZH2.
Status | Recruiting |
Enrollment | 210 |
Est. completion date | March 1, 2026 |
Est. primary completion date | December 31, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: Phase 1 Eligible Phase 1 patients are adults who have a confirmed locally advanced or metastatic tumors (solid tumors or lymphoma) that have relapsed following standard therapy or progressed through standard therapy or who have a disease for which no standard effective therapy exists. Phase 2: - Life expectancy of = 12 weeks - ECOG 0-1 - Adequate bone marrow function - Adequate renal function - Adequate liver function For Cohort M1, the following criteria should be considered: - Histologically confirmed locally advanced unresectable or metastatic urothelial carcinoma with predominant urothelial histology - • Histologically confirmed metastatic solid tumor (except ovarian clear cell cancer, endometrial cancer, and pleural or peritoneal mesothelioma) - Known ARID1A mutation (NGS testing) - Disease progression during or following prior chemotherapy approved therapies or for which no standard therapy exists - Measurable disease per RECIST 1.1 For Cohort M2, the following criteria should be considered: - Histologically confirmed advanced ovarian clear cell carcinoma - Known ARID1A mutation (by NGS testing) - Received at least 1 line of platinum-based chemotherapy and must have received bevacizumab as part of any line of treatments unless contraindicated or locally not approved or locally not accessible - Measurable disease per RECIST 1.1 - Patient must have disease progression after previously receiving effective and available standard of care treatment for clear cell ovarian cancer per local clinical practice For Cohort M3, the following criteria should be considered: - Histologically or cytologically confirmed recurrent, metastatic, or unresectable endometrial carcinoma - Known ARID1A mutation (by NGS testing) - Received at least 1 line of platinum-based regimen in recurrent/metastatic setting - Documented microsatellite instability (MSI)-high or deficient mismatch repair (dMMR) or patients who have non-dMMR/microsatellite stable tumors should have received an anti-PD-1 or anti-PD-L1 agent alone or in combination with the approved agents as applicable, as part of their prior treatments unless considered not eligible, contraindicated or if not locally approved - Brachytherapy is allowed if completed >12 weeks before the first dose of study drug - Measurable disease per RECIST 1.1 - Patients must have previously received effective and available standard of care treatment options for endometrial cancer per local clinical practice unless these are contraindicated For Cohort M4, the following criteria should be considered: - PTCL or DLBCL with the following criteria: - PTCL - Documented refractory, relapsed, or progressive disease after at least 1 prior line of systemic therapy. Refractory is defined as: - Failure to achieve CR after first-line therapy - Failure to reach at least PR after second-line therapy or beyond - Must have at least 1 prior line of systemic therapy for PTCL. - Participants must be considered hematopoietic cell transplantation (HCT) ineligible during screening due to disease status (active disease), comorbidities, or other factors; the reason for HCT ineligibility must be clearly documented. - In the PTCL cohort, participants with anaplastic large cell lymphoma (ALCL) must have prior brentuximab vedotin treatment. - DLBCL: - Relapsed or refractory disease following 2 or more prior lines of standard therapy. - Not considered candidates to receive CAR-T or autologous hematopoietic stem cell transplant (ASCT) as assessed by the treating investigator for reasons such as age, underlying comorbidities, performance status, or due to disease progression after previously received ASCT or CAR-T. The reason for transplant ineligibility must be clearly documented. - For patients who underwent past ASCT or CAR-T treatment, at least 90 days must have elapsed since the start of the procedure. For all other patients, at least 8 weeks must have elapsed since their most recent systemic anti-DLBCL therapy For Cohort M5, the following criteria should be considered: - Pleural or peritoneal relapsed/refractory mesothelioma - Must have progressed on or after at least 1 prior line of active therapy - Measurable disease per modified RECIST 1.1 for pleural mesothelioma or by RECIST 1.1 for peritoneal mesothelioma - Known BAP1 loss per immunohistochemistry (IHC) or NGS For Cohort M6, the following criteria should be considered: - Have measurable soft-tissue disease - Documented metastatic disease - Disease progression while on prior therapies - Baseline testosterone =50 ng/dL (=2.0 nM) and surgical or ongoing medical castration must be maintained throughout the duration of the study Exclusion Criteria Medical Conditions - Previous solid organ or allogeneic hematopoietic cell transplant (HCT) - Known symptomatic untreated brain metastases - Clinically significant cardiovascular disease - Major surgery within 4 weeks before starting study drug or not recovered from any effects of prior major surgery - Gastrointestinal disorders or any other condition that may significantly interfere with absorption of the study medication by Investigator's assessment. - Uncontrolled active infection requiring intravenous antibiotic, antiviral, or antifungal medications within 14 days before the first dose of study drug. Infections (eg, urinary tract infection) controlled on concurrent antimicrobial agents and antimicrobial prophylaxis per institutional guidelines are acceptable. - Suspected pneumonitis or interstitial lung disease or a history of pneumonitis or interstitial lung disease. - Have a history of a concurrent or second malignancy. Patients with a history of T-cell lymphoblastic lymphoma or T-Cell lymphoblastic leukemia are not eligible. - Have current known active or chronic infection with HIV, hepatitis B, or hepatitis C. Screening of patients with serologic testing for these viruses is not required - Clinically active or symptomatic viral hepatitis or chronic liver disease. - Unstable or severe uncontrolled medical condition or any important medical or psychiatric illness or abnormal laboratory finding - Previous solid organ or allogeneic hematopoietic cell transplant HCT. Prior/Concomitant Therapy: - Prior anticancer treatment: - Prior systemic anticancer treatment with chemotherapy, targeted therapy, small molecule, antibody, or investigational anticancer therapy (includes prior PD-1 or PD-L1 therapy), or other anticancer therapeutic with the exception of gonadotropin releasing hormone analogues, within 4 weeks (or 5 half-lives), whichever is shorter, before the first dose of study drug (6 weeks washout for nitrosoureas or mitomycin C). - Previous treatment with an EZH2 inhibitor - Prior radiation therapy within 4 weeks before first dose of study drug - Prior stereotactic body radiation therapy within 2 weeks before first dose of study drug - Prior chemoembolization or radioembolization within 4 weeks before first dose of study drug. - Concomitant medication(s) or food or beverage that are strong CYP3A inducers or inhibitors within 7 days prior to the first dose of study drug. Other Exclusions • Breastfeeding or pregnant woman or expecting to conceive or father children within the projected duration of the trial, starting with the Screening visit through 183 days after the last dose of study drug. Cohort M6 (mCRPC) only - Bone-only disease without nodal disease and no evidence of visceral spread - Structurally unstable bone lesions concerning for impending fracture - Herbal products that may decrease prostate-specific antigen within 4 weeks prior to Day 1 of treatment and while on study - Treatment for prostate cancer (First generation androgen receptor antagonists within 4 weeks; 5a-reductase inhibitors, ketoconazole, estrogens, or progesterones within 2 weeks) - Planned palliative procedures such as radiation therapy or surgery |
Country | Name | City | State |
---|---|---|---|
France | Bergonie Institute | Bordeaux | |
France | Oscar Lambret Center | Lille | |
France | Leon Berard Center | Lyon | |
France | Hospital North | Nantes | |
France | Nantes University Hospital Center - Hotel Dieu Hospital | Nantes | |
France | Nantes University Hospital Center - Hotel Dieu Hospital (Satellite) | Nantes | |
France | Strasbourg Europe Institut of Cancerology | Strasbourg | |
France | Gustave Roussy | Villejuif | |
Italy | Irccs University Hospital of Bologna | Bologna | |
Italy | Gruppo Humanitas - Humanitas Research Hospital - Cancer Center | Milan | |
Italy | University Polyclinic Foundation "Agostino Gemelli" - IRCCS | Rome | |
Korea, Republic of | Gangnam Severance Hospital | Seoul | |
Poland | Polish Mother's Memorial Hospital-Research Institute | Lodz | |
Poland | Medical Center Pratia Poznan | Skorzewo, | |
Poland | Maria Sklodowska-Curie - National Research Institute of Oncology | Warsaw | |
Spain | University Hospital Vall d'Hebron | Barcelona | |
Spain | University Hospital of Girona Dr. Josep Trueta | Girona | |
Spain | University Clinic of Navarra - Madrid | Madrid | |
Spain | University Hospital 12 de Octubre | Madrid | |
Spain | University Hospital Quiron Madrid | Madrid | |
Spain | University Hospital Son Espases | Palma De Mallorca | |
Spain | University Clinic of Navarra - Pamplona | Pamplona | |
Spain | University Clinical Hospital of Salamanca | Salamanca | Castilla Y Leon |
Spain | University Hospital Complex of Santiago (CHUS) | Santiago De Compostela | Galicia |
Spain | University Hospital Virgen del Rocio (HUVR) | Seville | |
Spain | Valencia Oncology Institute (IVO) | Valencia | |
United Kingdom | Royal United Hospital | Bath | |
United Kingdom | University Hospitals of Leicester NHS Trust | Leicester | |
United Kingdom | The Christie NHS Foundation Trust, Department of Medical Oncology | Manchester | |
United Kingdom | Royal Marsden Hospital - Sutton | Sutton | |
United Kingdom | Musgrove Park Hospital | Taunton | |
United States | University of Michigan Hospital | Ann Arbor | Michigan |
United States | Winship Cancer Institute of Emory University | Atlanta | Georgia |
United States | University of Maryland - Marlene and Stewart Greenebaum Cancer Center | Baltimore | Maryland |
United States | Dana Farber Cancer Institute | Boston | Massachusetts |
United States | Massachusetts General Hospital | Boston | Massachusetts |
United States | Montefiore Einstein Center for Cancer Care | Bronx | New York |
United States | University of Virginia Health System | Charlottesville | Virginia |
United States | University of Chicago Medical Center | Chicago | Illinois |
United States | University of Cincinnati Medical Center | Cincinnati | Ohio |
United States | South Texas Accelerated Research Therapeutics (Start) - Midwest Location | Grand Rapids | Michigan |
United States | Hackensack University Medical Center | Hackensack | New Jersey |
United States | NYU Langone Medical Center - Laura and Isaac Perlmutter Cancer Center | New York | New York |
United States | Weill Medical College of Cornell University | New York | New York |
United States | South Texas Accelerated Research Therapeutics | San Antonio | Texas |
United States | Fred Hutchinson Cancer | Seattle | Washington |
United States | Swedish Cancer Institute | Seattle | Washington |
Lead Sponsor | Collaborator |
---|---|
Constellation Pharmaceuticals |
United States, France, Italy, Korea, Republic of, Poland, Spain, United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Phase 1: Frequency of Dose-limiting toxicities (DLTs) | The maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D) of CPI-0209 in patients with advanced tumors | DLTs assessed during Cycle 1 (first 28 days on study) | |
Primary | Phase 2: Overall response rate (ORR) | ORR is defined as the proportion of patients with a best overall response of complete response (CR) or partial response (PR) based on RECIST 1.1 or applicable response criteria | 18 months | |
Secondary | Phase 1 Adverse events (AEs) and change in laboratory values | 18 months | ||
Secondary | Phase 1: PK parameters | Cmax | 18 months | |
Secondary | Phase 1: PK parameters | Tmax | 18 months | |
Secondary | Phase 1: PK parameters | AUC0-last | 18 months | |
Secondary | Phase 1: PK parameters | AUC0-Inf | 18 months | |
Secondary | Phase 1: PK parameters | t1/2 | 18 months | |
Secondary | Phase 1: PK parameters | Cmin | 18 months | |
Secondary | Phase 1: PD parameters | Gene expression in blood cells | 18 months | |
Secondary | Phase 1: PD parameters | H3K27me3 | 18 months | |
Secondary | Phase 1: ORR | ORR, defined as proportion of patients with a best overall response of CR or PR) based on RECIST 1.1 or applicable response criteria | 18 months | |
Secondary | Phase 1: ORR per Gynecologic Cancer | ORR per Gynecologic Cancer Intergroup (GCIG)-defined CA-125 response criteria (ovarian cancer patients) | 18 months | |
Secondary | Phase 1: ORR per prostate cancer | ORR per Prostate Cancer Clinical Trials Working Group 3 (PCWG3) | 18 months | |
Secondary | Phase 1: Progression-free survival (PFS) | PFS, defined as the time from first dose to confirmed disease progression or death | 18 months | |
Secondary | Phase 1: Duration of response (DOR) | DOR, defined as the time from the date of first response to the date of confirmed disease progression | 18 months | |
Secondary | Phase 1: Time to response (TTR) | Time to response, defined as the time from first dose to date of first response | 18 months | |
Secondary | Phase 1: Disease control rate | [Disease control rate, defined as the proportion of patients with a best overall response of CR, PR, or stable disease | 18 months | |
Secondary | Phase 2: PFS | PFS, defined as the time from first dose to confirmed disease progression or death | 30 months | |
Secondary | Phase 2: Time-to-progression | Time-to-progression (TTP) | 30 months | |
Secondary | Phase 2: DOR | DOR, defined as the time from the date of first response to the date of confirmed disease progression | 30 months | |
Secondary | Phase 2: TTR | TTR, defined as the time from first dose to date of first response | 30 months | |
Secondary | Phase 2: Disease control rate | Disease control rate, defined as the proportion of patients with a best overall response of CR, PR or SD per cohort and CPI-0209 dose level | 30 months | |
Secondary | Phase 2: ORR | ORR per GCIG-defined CA-125 response criteria (ovarian cancer patients) | 30 months | |
Secondary | Phase 2: Overall survival (OS) | OS, defined as the time from first dose to death | 30 months | |
Secondary | Phase 2: Incidences of AEs | Number of Participants With Adverse Events (AEs) | 30 months | |
Secondary | Phase 2: PK parameters | Cmax | 30 months | |
Secondary | Phase 2: PK parameters | Tmax | 30 months | |
Secondary | Phase 2: PK parameters | AUC0-last | 30 months | |
Secondary | Phase 2: PK parameters | AUC0-inf | 30 months | |
Secondary | Phase 2: PK parameters | T1/2 | 30 months | |
Secondary | Phase 2: PK parameters | Cmin | 30 months | |
Secondary | Phase 2: PD parameters | Gene expression in blood cells | 30 months | |
Secondary | Phase 2: PD parameters | H3K27me3 levels | 30 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05796518 -
Feasibility of a Patient Directed Tool to Assess Heart Health Among Endometrial Cancer Survivors
|
N/A | |
Recruiting |
NCT05489211 -
Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
|
Phase 2 | |
Active, not recruiting |
NCT03667716 -
COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.
|
Phase 1 | |
Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT06463028 -
Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel, Serabelisib With Paclitaxel, and Paclitaxel Alone in Patients With Advanced/Recurrent Endometrial Cancer
|
Phase 2 | |
Recruiting |
NCT06036836 -
Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010)
|
Phase 2 | |
Terminated |
NCT04586335 -
Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors.
|
Phase 1 | |
Completed |
NCT03820024 -
MOtiVating Endometrial Cancer Survivors With Activity Monitors and Tailored Feedback
|
N/A | |
Active, not recruiting |
NCT05082025 -
Phase 2 Study of PI3K Inhibitor Copanlisib in Combination With Fulvestrant in Selected ER+ and/or PR+ Cancers With PI3K (PIK3CA, PIK3R1) and/or PTEN Alterations
|
Phase 2 | |
Active, not recruiting |
NCT00587886 -
Estrogen, Diet, Genetics and Endometrial Cancer
|
||
Completed |
NCT05378152 -
Assessing the Benefit of Pipelle Biopsy in Patients With Postmenopausal Bleeding and an Atrophic-appearing Cavity
|
N/A | |
Suspended |
NCT05124743 -
HLA Typing & Tumor Neoantigen Identification for Phase I/II Study of Autologous TCR-T Cells in Subjects With Solid Tumors
|
||
Recruiting |
NCT03876860 -
An Enhanced Vaginal Dilator to Reduce Radiation-Induced Vaginal Stenosis
|
N/A | |
Recruiting |
NCT04569773 -
Choosing Ovarian Preservation or Removal Before Surgery for Endometrial Cancer
|
||
Completed |
NCT04534309 -
Behavioral Weight Loss Program for Cancer Survivors in Maryland
|
N/A | |
Not yet recruiting |
NCT06366347 -
ALPINE: Maintenance Letrozole/Abemaciclib vs Pembrolizumab
|
Phase 2 | |
Not yet recruiting |
NCT06073184 -
Weight-loss Drug for Fertility-Sparing Treatment of Atypical Hyperplasia and Grade 1 Cancer of the Endometrium
|
Phase 2 | |
Not yet recruiting |
NCT05998798 -
Revealing Engagement Patterns Among Endometrial Cancer Patients
|
||
Terminated |
NCT02907073 -
Positron Emission Tomography (PET) Imaging Studies With NIS Reporter
|
Phase 1/Phase 2 | |
Completed |
NCT02413606 -
ENdometrial Cancer SURvivors' Follow-up carE (ENSURE): Less is More?
|
N/A |